Fig. 6

i-PCSK9 ameliorated the ability of i-miR-15b against LPS-related inflammation. A Hsa-miR-15b-5p levels and B immunoblotting of SIRT4. Mean ± SD, n = 3. M,  molecular weight markers; lane 1, Ctr; lane 2, LPS; lane 3, i-PCSK9; lane 4, i-PCSK9 + LPS. Detection of C ICAM1, D VCAM1, E MCP-1, F IL-1β, and G IL-18. Mean ± SD, n = 3. ^‡p < 0.01 versus Ctr or NC, ^¶p < 0.001 versus Ctr, ^§p < 0.001 versus NC, ^•p < 0.05 versus LPS or NC + LPS, ^†p < 0.01 versus NC + LPS, °p < 0.05 versus i-miR-15b + LPS. Statistical analysis of data was performed using one-way ANOVAs.